ERBB2 and breast cancer: In humans, a phase I clinical trial was performed to evaluate the toxicity, distribution and uptake of a targeted radionuclide theranostic agent directed at HER2+ BC, 131I‐GMIB‐anti‐HER2‐VHH1 [92].